Shopping Cart 0
Cart Subtotal
USD 0

Clovis Oncology Inc (CLVS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercializes rights for rociletinib, rucaparib and holds right in the US and Japan for lucitanib. Clovis has collaboration agreements with various companies such as Celgene Avilomics Research Inc.; Advenchen Laboratories LLC; Pfizer Inc. and Les Laboratoires Servier for the development and commercialization of its product candidates. The company operates offices in San Francisco and California, the US; Cambridge, the UK; and Milan, Italy. Clovis is headquartered in Boulder, Colorado, the US.

Clovis Oncology Inc (CLVS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Clovis Oncology Enters into Agreement with Immunomedics 12

Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13

Clovis Oncology Enters into Agreement with Strata Oncology 14

Clovis Oncology Enters into Agreement with Genentech 15

Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16

Licensing Agreements 17

Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17

Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18

Equity Offering 19

Clovis Oncology Raises USD100 Million in Public Offering of Shares 19

Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21

Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23

Clovis Oncology Raises USD316 Million in Public Offering of Shares 25

Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27

Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29

Debt Offering 31

Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31

Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32

Acquisition 33

Clovis Oncology Acquires EOS For USD 420 Million 33

Clovis Oncology Inc-Key Competitors 35

Clovis Oncology Inc-Key Employees 36

Clovis Oncology Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Oct 30, 2018: Clovis Oncology announces third quarter 2018 operating results 38

Aug 01, 2018: Clovis Oncology announces second quarter 2018 operating results 41

May 08, 2018: Clovis Oncology Reports First Quarter 2018 Operating Results 44

Feb 26, 2018: Clovis Oncology Announces 2017 Financial Results 47

Nov 01, 2017: Clovis Oncology Announces Third Quarter 2017 Operating Results 50

Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results 53

May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results 56

Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results 59

Corporate Communications 61

Oct 11, 2018: Clovis Oncology appoints two new Directors to its Board 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Clovis Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Clovis Oncology Enters into Agreement with Immunomedics 12

Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13

Clovis Oncology Enters into Agreement with Strata Oncology 14

Clovis Oncology Enters into Agreement with Genentech 15

Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16

Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17

Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18

Clovis Oncology Raises USD100 Million in Public Offering of Shares 19

Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21

Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23

Clovis Oncology Raises USD316 Million in Public Offering of Shares 25

Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27

Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29

Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31

Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32

Clovis Oncology Acquires EOS For USD 420 Million 33

Clovis Oncology Inc, Key Competitors 35

Clovis Oncology Inc, Key Employees 36

Clovis Oncology Inc, Other Locations 37

Clovis Oncology Inc, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Clovis Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercializes rights for rociletinib, rucaparib and holds right in the US and Japan for lucitanib. Clovis has collaboration agreements with various companies such as Celgene Avilomics Research Inc.; Advenchen Laboratories LLC; Pfizer Inc. and Les Laboratoires Servier for the development and commercialization of its product candidates. The company operates offices in San Francisco and California, the US; Cambridge, the UK; and Milan, Italy. Clovis is headquartered in Boulder, Colorado, the US.

Clovis Oncology Inc (CLVS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Clovis Oncology Enters into Agreement with Immunomedics 12

Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13

Clovis Oncology Enters into Agreement with Strata Oncology 14

Clovis Oncology Enters into Agreement with Genentech 15

Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16

Licensing Agreements 17

Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17

Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18

Equity Offering 19

Clovis Oncology Raises USD100 Million in Public Offering of Shares 19

Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21

Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23

Clovis Oncology Raises USD316 Million in Public Offering of Shares 25

Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27

Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29

Debt Offering 31

Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31

Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32

Acquisition 33

Clovis Oncology Acquires EOS For USD 420 Million 33

Clovis Oncology Inc-Key Competitors 35

Clovis Oncology Inc-Key Employees 36

Clovis Oncology Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Oct 30, 2018: Clovis Oncology announces third quarter 2018 operating results 38

Aug 01, 2018: Clovis Oncology announces second quarter 2018 operating results 41

May 08, 2018: Clovis Oncology Reports First Quarter 2018 Operating Results 44

Feb 26, 2018: Clovis Oncology Announces 2017 Financial Results 47

Nov 01, 2017: Clovis Oncology Announces Third Quarter 2017 Operating Results 50

Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results 53

May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results 56

Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results 59

Corporate Communications 61

Oct 11, 2018: Clovis Oncology appoints two new Directors to its Board 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Clovis Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Clovis Oncology Enters into Agreement with Immunomedics 12

Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13

Clovis Oncology Enters into Agreement with Strata Oncology 14

Clovis Oncology Enters into Agreement with Genentech 15

Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16

Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17

Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18

Clovis Oncology Raises USD100 Million in Public Offering of Shares 19

Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21

Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23

Clovis Oncology Raises USD316 Million in Public Offering of Shares 25

Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27

Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29

Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31

Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32

Clovis Oncology Acquires EOS For USD 420 Million 33

Clovis Oncology Inc, Key Competitors 35

Clovis Oncology Inc, Key Employees 36

Clovis Oncology Inc, Other Locations 37

Clovis Oncology Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Clovis Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.